Faron Pharmaceuticals Oy
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 7, 2027The maintenance fee for Cell and therapeutical and diagnostical methods based thereon (US 10,526,607) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,727,521 | Method of ameliorating multi-organ failure resulting from ischemic reperfusion injury In force · From the USPTO record | In force | From the USPTO record | |
| US 8,975,081 | Biomarker for Monitoring Development of Diseases and Assessing the Efficacy of Therapies In force · Medium confidence | In force | Medium confidence | |
| US 10,526,607 | Cell and therapeutical and diagnostical methods based thereon In force · From the USPTO record | In force | From the USPTO record | |
| US 8,722,045 | Cell and therapeutical and diagnostical methods based thereon In force · From the USPTO record | In force | From the USPTO record | |
| US 10,247,730 | Method for determining acute respiratory distress syndrome (ARDS) related biomarkers, a method to monitor the development and treatment of ARDS in a patient In force · From the USPTO record | In force | From the USPTO record | |
| US 10,293,030 | Lyophilised Pharmaceutical Formulation and Its Use In force · High confidence | In force | High confidence | |
| US 10,884,000 | Method of Monitoring the Efficacy of the ANTI-CLEVER-1 Therapy in Cancer In force · High confidence | In force | High confidence | |
| US 11,046,761 | Humanized Anti CLEVER-1 Antibodies and Their Use In force · High confidence | In force | High confidence | |
| US 11,421,279 | Method for Determining Patient's Responsiveness to Type 1 Interferon Treatment and Use of Type 1 Interferon to Treat Patient Having Specified Single Nucleoide Polymophism In force · High confidence | In force | High confidence | |
| US 12,472,235 | Treatment of Diseases with Sequential Administration of an Agent Capable of Up-Regulating CD73 and Glucocorticoids In force · High confidence | In force | High confidence |
Also on record, not counted in the 13: 1 lapsed for an unpaid fee · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 9 no status recorded